Use of Hydrochlorothiazide in the United States Following Label Update About Skin Cancer Risk
We did not observe significant changes in HCTZ use following the DSC about its NMSC risk, among the overall population and those with a history of NMSC. Our findings were in accordance with the DSC recommendation.
Authors
- Ashish Rai (ORCID: https://orcid.org/0000-0001-7131-7580)
- Jenice S. Ko
- Laura Hou (ORCID: https://orcid.org/0000-0003-0847-2574)
- Cheng Chen (ORCID: https://orcid.org/0000-0002-3240-8153)
- Mingfeng Zhang (ORCID: https://orcid.org/0000-0001-5951-8830)
- José J. Hernández‐Muñoz (ORCID: https://orcid.org/0000-0002-2553-3159)
- Mary Southworth
- Efe Eworuke (ORCID: https://orcid.org/0000-0001-8971-9748)
Institutions
- Center for Drug Evaluation and Research (US)
- Harvard University (US)
- IQVIA (United States) (US)
- Harvard Pilgrim Health Care (US)
- IQ Solutions (US)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/pds.70040
- Citations
- 4
- Primary Topic
- Skin Protection and Aging
- Type
- article
- Field-Weighted Citation Impact
- 2.14
Funders
- U.S. Food and Drug Administration
- Food and Drug Administration